Aprea Therapeutics Reports Positive Phase 1 Trial Results for Cancer Treatment APR-1051

Aprea Therapeutics (Nasdaq: APRE) announced positive preliminary data from its Phase 1 ACESOT-1051 clinical trial evaluating APR-1051, a targeted WEE1 inhibitor. The company reported a second partial response in a patient, showing a 50% reduction in tumor size and a significant decrease in the CA-125 biomarker at a 220 mg dose level. These emerging clinical proof-of-concept results highlight the drug's potential efficacy in treating specific cancer mutations, particularly those with PPP2R1A mutations. Notably, the trial has not observed any class-limiting toxicities to date, suggesting a favorable safety profile compared to existing treatments. This development marks a significant milestone for Aprea as it seeks to differentiate its therapeutic pipeline in the oncology space. Investors view these results as a critical de-risking event for the clinical-stage biotech company, potentially driving upward pressure on the stock.